Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eribulin in pediatric relapsed/refractory sarcomas
NCT03441360Phase 2Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Apr 2018
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of eribulin in rhabdomyosarcoma (RMS), soft tissue sarcoma (STS), Ewing sarcoma, sponsored by Eisai Co., Ltd.. Started Apr 2018; status: completed.
02
Drugs
eribulin
03
Conditions
rhabdomyosarcoma (RMS)soft tissue sarcoma (STS)Ewing sarcoma
Beyond the preview
Go deeper on NCT03441360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03441360.